Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Equity Average (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed Equity Average for 6 consecutive years, with $3.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average fell 49.22% to $3.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.6 million, a 49.22% decrease, with the full-year FY2024 number at $4.2 million, up 60.5% from a year prior.
  • Equity Average was $3.6 million for Q3 2025 at Vivos Therapeutics, down from $4.5 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $34.5 million in Q3 2021 to a low of $228500.0 in Q4 2023.
  • A 5-year average of $11.1 million and a median of $7.0 million in 2024 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: plummeted 96.88% in 2023, then skyrocketed 3317.72% in 2024.
  • Vivos Therapeutics' Equity Average stood at $29.0 million in 2021, then crashed by 74.73% to $7.3 million in 2022, then tumbled by 96.88% to $228500.0 in 2023, then surged by 3317.72% to $7.8 million in 2024, then plummeted by 54.45% to $3.6 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Equity Average are $3.6 million (Q3 2025), $4.5 million (Q2 2025), and $6.2 million (Q1 2025).